Overview

A Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Status:
Active, not recruiting

Trial end date:
2022-05-15

Target enrollment:

Participant gender:

Summary

This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension

Phase:

Phase 3

Details

Lead Sponsor:

Allergan

Treatments:

Bimatoprost